Lena Jendeberg Ph.D
Vice President, Development

Joining Modus Therapeutics in 2016, Lena Jendeberg has more than 20 years of experience in research and drug development in biotech and pharma, ranging from early target discovery through clinical development to life-cycle management of products on the market. She brings experience from project leadership in a wide range of different therapeutic areas including hemophilia, inflammation and metabolic diseases, as well as pediatric and orphan disease development knowledge. Prior to joining Modus Therapeutics, she held a position as Program Director, Inflammation at Sobi where she was responsible for further development and registration of the product Kineret for new indications. Lena has an M.Sc in Chemical Engineering and Ph.D in Biochemistry from the Royal Institute of Technology in Stockholm.


Telephone: +46 (0)70 695 23 92